After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has ...

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's ...

Reaffirms full-year 2025 Revenue guidance of $61.0 to $64.0 billion. Raises and narrows Adjusted (2) diluted EPS guidance (1) ...

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

$2.2 billion invested in internal research and development projects, and Approximately $90 million invested in business development transactions. Returning capital directly to shareholders through ...